Japan-headquartered Shimadzu Corporation has announced its investment in US-based Sepragen Corporation, a leading company specialising in the manufacturing and sales of innovative bioprocess chromatography systems used in the production of biopharmaceuticals.

In addition to this investment, Shimadzu has entered into a strategic partnership agreement with Sepragen. Starting in November 2024, Shimadzu will exclusively market and service Sepragen’s products in Japan, South Korea, and Southeast Asia, marking its entry into the growing biopharmaceutical market, particularly in the purification of vaccine and gene therapy drug manufacturing.

Shimadzu has a long-standing history of providing analytical and measuring instruments and technologies, such as liquid chromatography (HPLC), for research and quality control in the pharmaceutical industry. With this latest investment and partnership, Shimadzu can now offer comprehensive solutions from research and development to manufacturing in the pharmaceutical sector, including biopharmaceuticals.

Moving forward, Shimadzu will create synergies between its analytical technologies and Sepragen’s biomanufacturing technologies, aiming to establish robust methods for analysis and evaluation within the purification process.